Copy For Citation
Özen S., Sag E., Ben-Chetrit E., Gattorno M., Gül A., Hashkes P. J., ...More
Rheumatology (Oxford, England), vol.60, pp.3799-3808, 2021 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
60
-
Publication Date:
2021
-
Doi Number:
10.1093/rheumatology/keaa863
-
Journal Name:
Rheumatology (Oxford, England)
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
-
Page Numbers:
pp.3799-3808
-
Keywords:
inflammation, autoinflammatory conditions, quality of life care, outcome measures, DMARD, CHILDREN, RECOMMENDATIONS, MANAGEMENT, FMF
-
Hacettepe University Affiliated:
Yes
Abstract
Objectives. Colchicine is the main treatment for FMF. Although a number of individuals with FMF are intolerant/resistant to colchicine, there is no standard definition of colchicine resistance/intolerance. We developed a set of evidence-based core statements defining colchicine resistance/intolerance in patients with FMF that may serve as a guide for clinicians and health authorities.